Few Antidiabetic Drugs

Buformin

(US Adopted Name, rINN)

Drug Nomenclature

Synonyms: Buformina; DBV; W-37
USAN: Buformin
INN: Buformin [pINN (en)]
INN: Buformina [pINN (es)]
INN: Buformine [pINN (fr)]
INN: Buforminum [pINN (la)]
INN: Буформин [pINN (ru)]
Chemical name: 1-Butylbiguanide
Molecular formula: C6H15N5 =157.2
CAS: 692-13-7 (buformin); 1190-53-0 (buformin hydrochloride)
ATC code: A10BA03

Profile

Buformin is a biguanide antidiabetic. It has been given orally in the treatment of type 2 diabetes mellitus in doses of up to 300 mg daily. Buformin is also used as the hydrochloride.

Proprietary Preparations

Czech Republic: Adebit † Silubin- †

Hungary: Adebit

Spain: Silubin †

Switzerland: Silubin †

Carbutamide

Drug Approvals

(British Approved Name, rINN)

International Nonproprietary Names (INNs) in main languages (French, Latin, Spanish):

Synonyms: BZ-55; Ca-1022; Carbutamida; Carbutamidum; Glybutamide; Karbutamid; Karbutamidi; U-6987
BAN: Carbutamide
INN: Carbutamide [rINN (en)]
INN: Carbutamida [rINN (es)]
INN: Carbutamide [rINN (fr)]
INN: Carbutamidum [rINN (la)]
INN: Карбутамид [rINN (ru)]
Chemical name: 1-Butyl-3-sulphanilylurea
Molecular formula: C11H17N3O3S =271.3
CAS: 339-43-5
ATC code: A10BB06

Profile

Carbutamide is a sulfonylurea antidiabetic. It is given orally in the treatment of type 2 diabetes mellitus in single daily doses of 0.5 to 1 g, but is more toxic than chlorpropamide.

Proprietary Preparations

France: Glucidoral

Epalrestat

(rINN)

Drug Nomenclature

Synonyms: Epalrestat; ONO-2235
INN: Epalrestat [rINN (en)]
INN: Epalrestat [rINN (es)]
INN: Épalrestat [rINN (fr)]
INN: Epalrestatum [rINN (la)]
INN: Епалрестат [rINN (ru)]
Chemical name: 5-[(Z,E)-β-Methylcinnamylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid
Molecular formula: C15H13NO3S2 =319.4
CAS: 82159-09-9

Profile

Epalrestat inhibits the enzyme aldose reductase which catalyses the conversion of glucose to sorbitol. It has been suggested that accumulation of sorbitol in certain cells, occurring only in conditions of hyperglycaemia and resulting in a hyperosmotic effect, may be involved in the pathogenesis of some diabetic complications. Aldose reductase inhibitors have no influence on blood-glucose concentrations. Epalrestat is given orally for the treatment of diabetic complications including neuropathy, in a usual dose of 50 mg three times daily before meals.

Proprietary Preparations

Japan: Kinedak

Glibornuride

Drug Approvals

(British Approved Name, US Adopted Name, rINN)

INNs in other languages (French, Latin, and Spanish):

Synonyms: Glibornurid; Glibornurida; Glibornuridi; Glibornuridum; Ro-6-4563
USAN: Glibornuride
INN: Glibornuride [rINN (en)]
INN: Glibornurida [rINN (es)]
INN: Glibornuride [rINN (fr)]
INN: Glibornuridum [rINN (la)]
INN: Глиборнурид [rINN (ru)]
Chemical name: 1-[(2S,3R)-2-Hydroxyborn-3-yl]-3-tosylurea; 1-[(2S,3R)-2-Hydroxyborn-3-yl]-3-p-tolylsulphonylurea
Molecular formula: C18H26N2O4S =366.5
CAS: 26944-48-9
ATC code: A10BB04
Read code: y00Rb

Note. The name glibornuride has frequently but erroneously been applied to glibenclamide.

Profile

Glibornuride is a sulfonylurea antidiabetic. It is given orally in the treatment of type 2 diabetes mellitus in doses of 12.5 to 75 mg daily. Daily doses of 50 mg or more are given in 2 divided doses.

Proprietary Preparations

Austria: Glutril

France: Glutril

Germany: Gluborid Glutril

Switzerland: Gluborid Glutril

Turkey: Glutril

Glisentide

Drug Nomenclature

Synonyms: Glipentide; Glisentida
INN: Glisentide [rINN (en)]
INN: Glisentida [rINN (es)]
INN: Glisentide [rINN (fr)]
INN: Glisentidum [rINN (la)]
INN: Глизентид [rINN (ru)]
Chemical name: 1-Cyclopentyl-3-[p-(2-o-anisamidoethyl)benzenesulphonyl]urea
Molecular formula: C22H27N3O5S =445.5
CAS: 32797-92-5

Profile

Glisentide is a sulfonylurea antidiabetic. It is given orally in the treatment of type 2 diabetes mellitus in doses of 2.5 to 20 mg daily.

Proprietary Preparations

Spain: Staticum

Glisolamide

Drug Nomenclature

INN: Glisolamide [rINN (en)]
INN: Glisolamida [rINN (es)]
INN: Glisolamide [rINN (fr)]
INN: Glisolamidum [rINN (la)]
INN: Глизоламид [rINN (ru)]
Chemical name: 1-Cyclohexyl-3-{p-[2-(5-methylisoxazole-3-carboxamido)ethyl]benzenesulphonyl}urea
Molecular formula: C20H26N4O5S =434.5
CAS: 24477-37-0

Profile

Glisolamide is a sulfonylurea antidiabetic. It has been given in the treatment of type 2 diabetes mellitus.

Proprietary Preparations

Italy: Diabenor

Glisoxepide

Drug Nomenclature

Synonyms: Bay-b-4231; FBB-4231; Glisoxepid; Glisoxepida; RP-22410
BAN: Glisoxepide
INN: Glisoxepide [rINN (en)]
INN: Glisoxepida [rINN (es)]
INN: Glisoxépide [rINN (fr)]
INN: Glisoxepidum [rINN (la)]
INN: Глизоксепид [rINN (ru)]
Chemical name: 1-(Perhydroazepin-1-yl)-3-{4-[2-(5-methylisoxazole-3-carboxamido)ethyl]benzenesulphonyl}urea
Molecular formula: C20H27N5O5S =449.5
CAS: 25046-79-1
ATC code: A10BB11

Profile

Glisoxepide is a sulfonylurea antidiabetic. It has been given in the treatment of type 2 diabetes mellitus.

Proprietary Preparations

Austria: Pro-Diaban

Glybuzole

Drug Nomenclature

Synonyms: AN-1324; Désaglybuzole; Glibuzol; RP-7891
INN: Glybuzole [rINN (en)]
INN: Glibuzol [rINN (es)]
INN: Glybuzole [rINN (fr)]
INN: Glybuzolum [rINN (la)]
INN: Глибузол [rINN (ru)]
Chemical name: N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)benzenesulphonamide
Molecular formula: C12H15N3O2S2 =297.4
CAS: 1492-02-0

Profile

Glybuzole is an oral antidiabetic with a structure distinct from that of the sulfonylureas, biguanides, or sulfonamidopyrimidines.

Proprietary Preparations

Japan: Gludiase

Glycyclamide

Drug Nomenclature

Synonyms: Gliciclamida; Gliciclamide; K-38; K-386; Tolcyclamide
INN: Glycyclamide [rINN (en)]
INN: Gliciclamida [rINN (es)]
INN: Glycyclamide [rINN (fr)]
INN: Glycyclamidum [rINN (la)]
INN: Глицикламид [rINN (ru)]
Chemical name: 1-Cyclohexyl-3-tosylurea; 1-Cyclohexyl-3-p-tolylsulphonylurea
Molecular formula: C14H20N2O3S =296.4
CAS: 664-95-9

Profile

Glycyclamide is a sulfonylurea antidiabetic. It is given by mouth in the treatment of type 2 diabetes mellitus.

Preparations

Proprietary Preparations

Italy: Diaborale

Mitiglinide

INN: Mitiglinide [rINN (en)]
INN: Mitiglinida [rINN (es)]
INN: Mitiglinide [rINN (fr)]
INN: Mitiglinidum [rINN (la)]
INN: Митиглинид [rINN (ru)]
Chemical name: (-)-(2S,3a,7a-cis)-αBenzylhexahydro-γ-oxo-2-isoindolinebutyric acid
Molecular formula: C19H25NO3 =315.4
CAS: 145375-43-5 (mitiglinide); 145525-41-3 (anhydrous mitiglinide calcium); 207844-01-7 (mitiglinide calcium dihydrate)

Profile

Mitiglinide is a meglitinide antidiabetic that is under investiga tion in the treatment of type 2 diabetes mellitus.

Muraglitazar

Synonyms: BMS-298585
USAN: Muraglitazar
INN: Muraglitazar [rINN (en)]
INN: Muraglitazar [rINN (es)]
INN: Muraglitazar [rINN (fr)]
INN: Muraglitazarum [rINN (la)]
INN: Мураглитазар [rINN (ru)]
Chemical name: {[(4-Methoxyphenoxy)carbonyl]{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzyl}amino}acetic acid
Molecular formula: C29H28N2O7 =516.5
CAS: 331741-94-7

Profile

Muraglitazar is a dual alfa/gamma peroxisome proliferator-activated receptor (PPAR) activator. It has been investigated in the treatment of type 2 diabetes mellitus.

Adverse effects. A review of data from 5 studies suggested that muraglitazar may be associated with an increased risk of adverse cardiovascular events and heart failure.

Phenformin Hydrochloride

Synonyms: Fenformina Cloridrato; Fenformina, hidrocloruro de
BAN: Phenformin Hydrochloride [BANM]
INN: Phenformin Hydrochloride [pINNM (en)]
INN: Hidrocloruro de fenformina [pINNM (es)]
INN: Phenformine, Chlorhydrate de [pINNM (fr)]
INN: Phenformini Hydrochloridum [pINNM (la)]
INN: Фенформина Гидрохлорид [pINNM (ru)]
Chemical name: 1-Phenethylbiguanide hydrochloride
Molecular formula: C10H15N5,HCl =241.7
CAS: 114-86-3 (phenformin); 834-28-6 (phenformin hydrochloride)
ATC code: A10BA01

Pharmacopoeias. In China

Profile

Phenformin hydrochloride is a biguanide antidiabetic. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries for the treatment of type 2 diabetes mellitus.

Phenformin was implicated in the controversial reports of excess cardiovascular mortality associated with oral hypoglycaemic therapy (see under Sulfonylureas, Effects on the Cardiovascular System).

Proprietary Preparations

Greece: Informin

India: DBI

Portugal: Debeina

Multi-ingredient

Greece: Daopar †

India: Chlorformin †

Italy: Bi-Euglucon Bidiabe Gliben  † Gliformin Suguan

Pimagedine

INN: Pimagedine [rINN (en)]
INN: Pimagedina [rINN (es)]
INN: Pimagédine [rINN (fr)]
INN: Pimagedinum [rINN (la)]
INN: Пимагедин [rINN (ru)]
Chemical name: Aminoguanidine
Molecular formula: CH6N4 =74.09
CAS: 79-17-4

Pimagedine Hydrochloride

Drug Approvals

(US Adopted Name, rINNM)

INNs in main languages (French, Latin, and Spanish):

Synonyms: GER-11
USAN: Pimagedine Hydrochloride
INN: Pimagedine Hydrochloride [rINNM (en)]
INN: Hidrocloruro de pimagedina [rINNM (es)]
INN: Pimagédine, Chlorhydrate de [rINNM (fr)]
INN: Pimagedini Hydrochloridum [rINNM (la)]
INN: Пимагедина Гидрохлорид [rINNM (ru)]
Chemical name: Aminoguanidine monohydrochloride
Molecular formula: CH6N4,HCl =110.5
CAS: 1937-19-5

Profile

Pimagedine reportedly inhibits the formation of glycosylated proteins (advanced glycosylation end-products) and has other actions including inhibition of aldose reductase. It has been investigated for the prevention of diabetic complications.

Ruboxistaurin

Synonyms: LY-333531; LY-341684 (ruboxistaurin mesilate)
INN: Ruboxistaurin [rINN (en)]
INN: Ruboxistaurina [rINN (es)]
INN: Ruboxistaurine [rINN (fr)]
INN: Ruboxistaurinum [rINN (la)]
INN: Рубоксистаурин [rINN (ru)]
Chemical name: (9S)-9-[(Dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,19H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-18,20-dione
Molecular formula: C28H28N4O3 =468.5
CAS: 169939-94-0 (ruboxistaurin); 169939-93-9 (ruboxistaurin hydrochloride); 202260-21-7 (ruboxistaurin mesilate)

Profile

Ruboxistaurin is an oral inhibitor of the p-isoform of the enzyme protein kinase C, which is thought to play a role in the development of diabetic microvascular complications. It is under investigation as an adjunct in the treatment of diabetic retinopathy.

Voglibose

Pharmacopoeias. In Japan.

Synonyms: A-71100; AO-128; Voglibosa
USAN: Voglibose
INN: Voglibose [rINN (en)]
INN: Voglibosa [rINN (es)]
INN: Voglibose [rINN (fr)]
INN: Voglibosum [rINN (la)]
INN: Воглибоза [rINN (ru)]
Chemical name: 3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-2-C-(hydroxymethyl)-D-epi-inositol
Molecular formula: C10H21NO7 =267.3
CAS: 83480-29-9
ATC code: A10BF03

Profile

Voglibose is an alpha-glue osidase inhibitor with general properties similar to those of acarbose. It is used in the treatment of diabetes mellitus in oral doses of 200 to 300 micrograms three times daily before meals.

Hepatic encephalopathy. Vbglibose has been investigated in the management of hepatic encephalopathy.

Proprietary Preparations

Japan: Basen

Philippines: Basen

Thailand: Basen.

Tagged , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Comments are closed.